17,261 trials
Irritable Bowel Syndrome With Diarrhea
Primary: Summary and Analysis of Overall Stool Consistency Response Rate - mITT Population — 42; 18; 33; 33 Participants — p=0.036
Anaplastic Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Complete Response Rate — 0 Participants
Post-Traumatic Headache
Primary: Number of Participants With Sustained Headache Relief — 12 Participants
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
Neutropenia
Primary: Participants With Adverse Events (AEs) — 2; 28; 16; 2 Participants
Breast Cancer
Primary: Absolute Change in Mean Proliferative Rate Measured by Ki67% — -1.15; 4 percentage of Ki67 — p=0.32
Depression
Primary: MADRS-S Score — 22.56; 23 units on a scale
Staphylococcal Infections
Primary: Percentage of Participants With At Least 1 Local Reaction Within 14 Days of Vaccination — 2.9; 20.6; 5.9; 29.4 Percentage of participants
Alzheimer's Disease
Primary: Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region — 0.0015; 0.0034; -0.0204; -0.0293 ratio
Ovarian Stimulation
Primary: Number of Oocytes Retrieved — 4.0; 3.5 Oocytes
Geographic Atrophy · Age-related Macular Degeneration
Primary: Part A: Geographic Atrophy (GA) Lesion Growth Measured by Fundus Autofluorescence (FAF) From Baseline to Day 505 — 1.95; 1.58 mm^2
Enterocolitis Clostridium Difficile Recurrent
Primary: Treatment Success of Group A (2 Doses of RBX2660) vs Group B (2 Doses of Placebo) (ITT) — 25; 19; 20; 25 Participants
Prostate Cancer
Primary: Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12 — 47; 89; 88; 22…
Metastatic ER+ Her2- Breast Cancer · Postmenopausal
Primary: Progression-Free Survival (PFS) — 3.68; 3.65; 4.47 Months — p=0.437
Cystic Fibrosis
Primary: Absolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28 — -0.5; -0.9 percentage of whole-lung clearance — p=0.7151